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Purpose: To update the American Society of Clinical Oncology (ASCO)/American Society of
Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients
with cancer.
Methods: PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs)
and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14,
2018. For biosimilar ESAs, the literature search was expanded to include meta-analyses and RCTs in
patients with cancer or chronic kidney disease and cohort studies in patients with cancer due to limited
RCT evidence in the cancer setting. ASCO and ASH convened an Expert Panel to review the evidence
and revise previous recommendations as needed.
Results: The primary literature review included 15 meta-analyses of RCTs and two RCTs. A growing
body of evidence suggests that adding iron to treatment with an ESA may improve hematopoietic
response and reduce the likelihood of RBC transfusion. The biosimilar literature review suggested that
biosimilars of epoetin alfa have similar efficacy and safety to reference products, although evidence in
cancer remains limited.
Recommendations: ESAs (including biosimilars) may be offered to patients with chemotherapy-
associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined
to , 10 g/dL. RBC transfusion is also an option. With the exception of selected patients with
myelodysplastic syndromes, ESAs should not be offered to most patients with nonchemotherapy-
associated anemia. During ESA treatment, hemoglobin may be increased to the lowest concentration
needed to avoid transfusions. Iron replacement may be used to improve hemoglobin response and
reduce RBC transfusions for patients receiving ESA with or without iron deficiency. Additional
information is available at www.asco.org/supportive-care-guidelines and www.hematology.org/
guidelines.
Introduction
Use of erythropoiesis-stimulating agents (ESAs) to manage anemia raises hemoglobin (HgB) levels
and reduces the need for RBC transfusions, but increases the risk of thromboembolic events.1,2
Studies have also reported decreased survival, increased mortality during active study phase, and/
or an increased risk of cancer progression or recurrence with the use of ESAs in patients with
cancer.3-6 The risks of ESAs prompted multiple regulatory actions by the US Food and Drug
Administration (FDA) between 2004 and 2009, and in 2010, the FDA approved a Risk Evaluation
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The bottom line
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice
guideline update
Guideline question
When and how should erythropoiesis-stimulating agents (ESAs) be used to manage anemia in adults with cancer?
Target population
Adults with cancer and anemia.
Target audience
Oncologists, hematologists, oncology nurses, oncology pharmacists, and other health care professionals who care for patients with
cancer, and patients with cancer.
Methods
An Expert Panel was convened to update clinical practice guideline recommendations based on a systematic review of the medical
literature.
Recommendations
Clinical question 1
To reduce the need for RBC transfusions, should ESAs be offered to patients who have chemotherapy-associated anemia?
Recommendation 1.1. Depending on clinical circumstances, ESAs may be offered to patients with chemotherapy-associated
anemia whose cancer treatment is not curative in intent and whose hemoglobin (HgB) has declined to , 10 g/dL. RBC
transfusion is also an option, depending on the severity of the anemia or clinical circumstances (Type: evidence based; Evidence
quality: high; Strength of recommendation: strong).
Recommendation 1.2. ESAs should not be offered to patients with chemotherapy-associated anemia whose cancer treatment is
curative in intent (Type: evidence based; Evidence quality: intermediate; Strength of recommendation: strong).
Clinical question 2
To reduce the need for RBC transfusions, should ESAs be offered to anemic patients with cancer who are not receiving concurrent
myelosuppressive chemotherapy?
Recommendation 2.1. ESAs should not be offered to most patients with nonchemotherapy-associated anemia (Type: informal
consensus; Evidence quality: low; Strength of recommendation: strong).
Recommendation 2.2. ESAs may be offered to patients with lower risk myelodysplastic syndromes and a serum erythropoietin
level # 500 IU/L (Type: evidence based; Evidence quality: intermediate; Strength of recommendation: moderate).
Clinical question 3
What special considerations apply to adult patients with nonmyeloid hematologic malignancies who are receiving concurrent myelo-
suppressive chemotherapy?
Recommendation 3. In patients with myeloma, non-Hodgkin lymphoma, or chronic lymphocytic leukemia, clinicians should observe the
hematologic response to cancer treatment before considering an ESA. Particular caution should be exercised in the use of ESAs
concomitant with treatment strategies and diseases where risk of thromboembolic complications is increased (see
Recommendations 4 and 6). In all cases, blood transfusion is a treatment option that should be considered (Type: informal
consensus; Evidence quality: low; Strength of recommendation: moderate).
Clinical question 4
What examinations and diagnostic tests should be performed before making a decision about using an ESA to identify patients who are
likely to benefit from an ESA?
Recommendation 4. Before offering an ESA, clinicians should conduct an appropriate history, physical examination, and diagnostic
tests to identify alternative causes of anemia aside from chemotherapy or an underlying hematopoietic malignancy. Such causes should
be appropriately addressed before considering the use of ESAs. Suggested baseline investigations are listed in Table 1 (Type: informal
consensus; Evidence quality: intermediate; Strength of recommendation: strong).
Clinical question 5
Among adult patients who receive an ESA for chemotherapy-associated anemia, do darbepoetin, epoetin beta and alfa originator, and
currently available biosimilars of epoetin alfa differ with respect to safety or efficacy?
Recommendation 5. The Expert Panel considers epoetin beta and alfa, darbepoetin, and biosimilar epoetin alfa to be equivalent
with respect to effectiveness and safety (Type: informal consensus; Evidence quality: intermediate; Strength of recommendation:
moderate).
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and Mitigation Strategy for ESA use in patients with cancer. In
2017, the FDA determined that the Risk Evaluation and Mitigation
Strategy was no longer necessary: prescribers demonstrated
acceptable knowledge of the risks of ESAs and the need to
counsel patients about the risks, and utilization data suggested
an increase in appropriate prescribing practices.7 The risks of
ESAs remain, however, highlighting the ongoing importance of
appropriate use. ESAs are indicated in patients with cancer who
are receiving myelosuppressive chemotherapy with noncurative
intent and anemia that cannot be adequately managed with
transfusional support.
The American Society of Clinical Oncology (ASCO) and the
American Society of Hematology (ASH) first published a joint
evidence-based clinical practice guideline for the use of ESAs in
adults with cancer and anemia in 2002,8 with updates in 20079 and
2010.10 Since the 2010 update, additional information has emerged
about the safety and efficacy of ESAs in patients with metastatic
breast cancer and about the role of iron in conjunction with
ESAs. Treatment options have also expanded with the 2018 FDA
approval of a biosimilar of epoetin alfa, warranting a guideline
update.11
Guideline questions
This clinical practice guideline addresses 10 clinical questions: (1)
To reduce the need for RBC transfusions, should ESAs be offered
to patients who have chemotherapy-associated anemia? (2) To
reduce the need for RBC transfusions, should ESAs be offered to
anemic patients with cancer who are not receiving concurrent
myelosuppressive chemotherapy? (3) What special considerations
apply to adult patients with nonmyeloid hematologic malignancies
The bottom line (continued)
Clinical question 6
Do ESAs increase the risk of thromboembolism?
Recommendation 6. ESAs increase the risk of thromboembolism, and clinicians should carefully weigh the risks of
thromboembolism and use caution and clinical judgment when considering use of these agents (Type: evidence based; Evidence
quality: high; Strength of recommendation: strong).
Clinical question 7
Among adult patients who will receive an ESA for chemotherapy-associated anemia, what are recommendations for ESA dosing and
dose modifications?
Recommendation 7. It is recommended that starting and modifying doses of ESAs follow FDA guidelines (see Table 2 for specific dosing
information; Type: informal consensus; Evidence quality: intermediate; Strength of recommendation: moderate).
Clinical question 8
Among adult patients who will receive an ESA for chemotherapy-associated anemia, what is the recommended target HgB level?
Recommendation 8. HgB may be increased to the lowest concentration needed to avoid or reduce the need for RBC transfusions,
which may vary by patient and condition (Type: informal consensus; Evidence quality: intermediate; Strength of recommendation:
moderate).
Clinical question 9
Among adult patients with chemotherapy-associated anemia who do not respond to ESA therapy (, 1 to 2 g/dL increase in HgB or no
decrease in transfusion requirements), does continuation of ESA therapy beyond 6 to 8 weeks provide a benefit?
Recommendation 9. ESAs should be discontinued in patients who do not respond within 6 to 8 weeks. Patients who do not respond to
ESA treatment should be reevaluated for underlying tumor progression, iron deficiency, or other etiologies for anemia (Type: informal
consensus; Evidence quality: intermediate; Strength of recommendation: strong).
Clinical question 10
Among adult patients with chemotherapy-associated anemia, does iron supplementation concurrent with an ESA reduce transfusion
requirements?
Recommendation 10. Iron replacement may be used to improve HgB response and reduce RBC transfusions for patients
receiving ESA with or without iron deficiency. Baseline and periodic monitoring of iron, total iron-binding capacity, transferrin
saturation, or ferritin levels is recommended (Type: evidence based; Evidence quality: intermediate; Strength of recommendation:
weak).
Additional resources
More information, including a Data Supplement with additional evidence tables, slide sets, and clinical tools and resources, is
available at www.asco.org/supportive-care-guidelines. Patient information is available at www.cancer.net. The Methodology Manual
(available at www.asco.org/guideline-methodology) provides additional information about the methods used to develop this guideline
update.
ASCO and ASH believe that cancer clinical trials are vital to inform medical decisions and improve cancer care, and
that all patients should have the opportunity to participate.
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who are receiving concurrent myelosuppressive chemotherapy? (4)
What examinations and diagnostic tests should be performed
before making a decision about using an ESA to identify patients
who are likely to benefit from an ESA? (5) Among adult patients who
receive an ESA for chemotherapy-associated anemia, do darbe-
poetin, epoetin beta and alfa originator, and currently available
biosimilars of epoetin alfa differ with respect to safety or efficacy?
(6) Do ESAs increase the risk of thromboembolism? (7) Among
adult patients who will receive an ESA for chemotherapy-
associated anemia, what are recommendations for ESA dosing
and dose modifications? (8) Among adult patients who will receive
an ESA for chemotherapy-associated anemia, what is the
recommended target HgB level? (9) Among adult patients with
chemotherapy-associated anemia who do not respond to ESA
therapy (, 1 to 2 g/dL increase in HgB or no decrease in transfusion
requirements), does continuation of ESA therapy beyond 6 to 8 weeks
provide a benefit? (10) Among adult patients with chemotherapy-
associated anemia, does iron supplementation concurrent with an ESA
reduce transfusion requirements?
Methods
Guideline update process
This systematic review-based guideline was developed by a
multidisciplinary Expert Panel (Appendix Table A1), which in-
cluded a patient representative and an ASCO guidelines staff
member with health research methodology expertise. The Expert
Panel met via webinar and corresponded through e-mail. Based
upon the consideration of the evidence, the authors were asked
to contribute to the development of the guideline, provide critical
review, and finalize the guideline recommendations. The guide-
line recommendations were sent for an open comment period
of 2 weeks, allowing the public to review and comment on the
recommendations after submitting a confidentiality agreement.
These comments were taken into consideration while finalizing the
recommendations. Members of the Expert Panel were responsible for
reviewing and approving the penultimate version of guideline, which
was then circulated for external review and submitted to the Journal
of Clinical Oncology (JCO) for editorial review and consideration for
publication. All ASCO guidelines are ultimately reviewed and
approved by the Expert Panel and the ASCO Clinical Practice
Guidelines Committee prior to publication. The guideline was also
reviewed and approved by the ASH Guideline Oversight Sub-
committee, the ASH Committee on Quality, and ASH Officers. All
funding for the administration of the project was provided by
ASCO.
The recommendations were developed using a systematic review
of the literature from January 31, 2010, through May 14, 2018,
and clinical experience. For all questions except the question on
biosimilars, PubMed and the Cochrane Library were searched for
randomized controlled trials (RCTs) and meta-analyses of RCTs.
Publications were included if they assessed the efficacy and safety
of ESAs in patients with cancer and included at least 50 patients
per arm. For the question on biosimilars, PubMed and the Cochrane
Library were searched for RCTs and meta-analyses of RCTs in
patients with cancer or chronic kidney disease (CKD), or cohort
studies in patients with cancer. For all questions, primary outcomes of
interest were mortality, frequency of RBC transfusion, thromboem-
bolic risk, and progression-free survival. In the case of biosimilars,
HgB response and immunogenicity were additional outcomes of
interest. Secondary outcomes included quality of life, fatigue,
and overall survival. Search terms are provided in the Data
Supplement.
Articles were excluded from the systematic review if they were
(1) meeting abstracts not subsequently published in peer-reviewed
journals; (2) editorials, commentaries, letters, news articles, case
reports, or narrative reviews; (3) published in a non-English language;
or (4) an RCT that was analyzed in an included meta-analysis.
The updated search was guided by the “signals”12 approach that is
designed to identify only new, potentially practice-changing data—
signals—that might translate into revised practice recommenda-
tions. The approach relies on targeted routine literature searching
and the expertise of Expert Panel members to help identify potential
signals. Before publication, a review of the guideline’s feasibility for
implementation was also conducted. Ratings for the type and
strength of the recommendation and the quality of evidence are
provided with each recommendation. The Methodology Manual
(available at www.asco.org/guideline-methodology) provides addi-
tional information about the methods used to develop this guideline
update.
The Expert Panel and guidelines staff will work with co-chairs to
keep abreast of the need for any substantive updates to the
guideline. Based on formal review of the emerging literature, ASCO
and ASH will determine the need to update. This is the most recent
information as of the publication date.
Guideline disclaimer
The Clinical Practice Guidelines and other guidance published
herein are provided by the American Society of Clinical Oncology,
Inc. (ASCO) and the American Society of Hematology (ASH) to
assist providers in clinical decision making. The information herein
should not be relied upon as being complete or accurate, nor
should it be considered as inclusive of all proper treatments or
methods of care or as a statement of the standard of care. With the
rapid development of scientific knowledge, new evidence may
emerge between the time information is developed and when it is
published or read. The information is not continually updated
and may not reflect the most recent evidence. The information
addresses only the topics specifically identified therein and is not
applicable to other interventions, diseases, or stages of diseases.
This information does not mandate any particular course of medical
care. Further, the information is not intended to substitute for the
independent professional judgment of the treating provider, as
the information does not account for individual variation among
patients. Recommendations reflect high, moderate, or low confi-
dence that the recommendation reflects the net effect of a given
course of action. The use of words like “must,” “must not,” “should,”
and “should not” indicates that a course of action is recommended
or not recommended for either most or many patients, but there is
latitude for the treating physician to select other courses of action in
individual cases. In all cases, the selected course of action should
be considered by the treating provider in the context of treating the
individual patient. Use of the information is voluntary. ASCO and
ASH provide this information on an “as is” basis and makes no
warranty, express or implied, regarding the information. ASCO and
ASH specifically disclaim any warranties of merchantability or
fitness for a particular use or purpose. ASCO and ASH assume no
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responsibility for any injury or damage to persons or property arising
out of or related to any use of this information, or for any errors or
omissions.
Guideline and conflicts of interest
The Expert Panel was assembled in accordance with ASCO’s
Conflict of Interest Policy Implementation for Clinical Practice
Guidelines (“Policy,” found at http://www.asco.org/rwc), with
additional policies mutually agreed upon with ASH. All members
of the Expert Panel completed ASCO’s disclosure form, which
requires disclosure of financial and other interests, including
relationships with commercial entities that are reasonably likely to
experience direct regulatory or commercial impact as a result of
promulgation of the guideline. Categories for disclosure include
employment; leadership; stock or other ownership; honoraria,
consulting or advisory role; speaker’s bureau; research funding;
patents, royalties, other intellectual property; expert testimony;
travel, accommodations, expenses; and other relationships. In
accordance with the Policy, the majority of the members of the
Expert Panel did not disclose any relationships constituting a
conflict under the Policy.
Results
The primary literature review included 15 meta-analyses of RCTs1,2,13-25
and two RCTs.6,26 Three meta-analyses15,20,22 addressed the addition
of iron to an ESA. The remaining 12 meta-analyses1,2,13,14,16-19,21,23-25
addressed ESA versus control (placebo or best standard therapy).
The quality of the meta-analyses varied based on AMSTAR2 criteria,
such as assessment and discussion of bias and heterogeneity. The
two RCTs consisted of a large phase III RCT in metastatic breast
cancer6 and a smaller trial in myelodysplastic syndrome (MDS).26
Evidence tables and quality assessments for included meta-analyses
and RCTs are provided in the Data Supplement.
For biosimilars, both of the included meta-analyses27,28 and one29 of
the two RCTs29,30 involved patients with CKD. The only RCT
in patients with cancer30 had a high likelihood of bias based on
inadequate sample size, lack of an intent-to-treat analysis, and
industry funding and authorship. The quality of the four included
cohort studies of biosimilars31-34 in patients with cancer was not
formally assessed.
Recommendations
Clinical question 1
To reduce the need for RBC transfusions, should ESAs be offered
to patients who have chemotherapy-associated anemia?
Recommendation 1.1
Depending on clinical circumstances, ESAs may be offered to
patients with chemotherapy-associated anemia whose cancer
treatment is not curative in intent and whose HgB has declined to
, 10 g/dL. RBC transfusion is also an option, depending on the
severity of the anemia or clinical circumstances (Type: evidence
based; Evidence quality: high; Strength of recommendation:
strong).
Recommendation 1.2
ESAs should not be offered to patients with chemotherapy-
associated anemia whose cancer treatment is curative in intent
(Type: evidence based; Evidence quality: intermediate; Strength
of recommendation: strong).
Literature review update and analysis. In the 2010 guideline,
use of ESAs in relation to intent of treatment (curative versus palliative)
was addressed in a Special Note. In this update, the Expert Panel
chose to address treatment intent in a recommendation.
The results of the updated systematic review confirmed that ESAs
reduce the risk for RBC transfusion1,2,6,18,19,21,24 and increase the
risk of thromboembolism.1,2,6,16,19,25 ESAs were associated with an
increased risk of on-study mortality in some1,2 but not all18,24 meta-
analyses. The two meta-analyses that reported nonsignificant
associations with on-study mortality focused on specific subgroups
of patients defined by cancer type24 or HgB level18 and included
relatively small sample sizes. Seven meta-analyses1,2,13,17,19,21,24
and an RCT6 reported on overall survival, with only one publication13
reporting a statistically significant association with ESA use. Aapro
et al13 reported an increased risk of death in ESA users (odds ratio,
1.20; 95% confidence interval [CI], 1.03 to 1.40) based on nine RCTs
in patients with breast cancer. Meta-analyses consistently reported
statistically significant reductions in fatigue with ESA use,1,2,14,23
but the effect sizes were small and unlikely to be clinically important.35
Little information about treatment intent is available from published
studies, but one RCT6 in the updated literature review restricted to
patients with metastatic breast cancer and one meta-analysis1
developed a decision model that incorporated intent of treatment.
The 2013 Agency for Healthcare Research and Quality meta-
analyses by Grant et al1 developed decision models for patients
treated with curative or noncurative intent. The models suggest
that ESAs increase quality-adjusted life-years but decrease life-
years in both the curative and noncurative setting. The 2016
noninferiority trial by Leyland-Jones et al6 compared epoetin alfa
to best supportive care in 2,098 patients with metastatic breast
cancer. The primary outcome of interest—progression-free
survival based on investigator-determined progressive disease—
did not meet noninferiority criteria (hazard ratio [HR] 1.09;
95% CI, 0.99 to 1.20; prespecified noninferiority margin was
1.15). In their conclusion, the investigators state, “In light of
these study results, RBC transfusion should be the preferred
approach for the management of anemia during first- or second-
line chemotherapy for metastatic breast cancer. If EPO is to be
used in the more advanced settings of metastatic breast cancer, this
should be done with caution and based on careful risk-benefit
assessment.”6 (p1205)
Subgroup analyses of ESA efficacy and safety by baseline HgB
were provided by four meta-analyses1,2,14,21 and one RCT.6 In the
2013 Agency for Healthcare Research and Quality meta-analysis
by Grant et al,1 patients who initiated ESA use at a lower HgB level
(# 10 g/dL) had a greater reduction in likelihood of RBC transfusion
than patients who initiated ESA use at a higher baseline HgB level
(relative risk, 0.46; 95% CI, 0.41 to 0.49, for patients with lower
HgB at ESA initiation, compared with relative risk, 0.71; 95% CI,
0.65 to 0.79, for patients with higher HgB at ESA initiation; P, .01
for interaction). The effects of ESA use on on-study mortality and
overall survival did not differ significantly by baseline HgB level. In
the 2012 Cochrane review by Tonia et al,2 three levels of baseline
HgB were analyzed:# 10 g/dL, 10 to 12 g/dL, and . 12 g/dL.
Patients with a baseline HgB level of 10 to 12 g/dL had the
greatest reduction in risk of RBC transfusion with ESA use. In the
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remaining two meta-analyses, baseline HgB did not significantly
modify the association between ESA use and fatigue14 or overall
survival.21 In the 2016 RCT by Leyland-Jones et al,6 the HRs for
progression-free survival were similar in patients with lower
and higher baseline HgB levels (HR, 1.11; 95% CI, 0.92 to 1.33,
for patients with baseline HgB , 10 g/dL; HR, 1.08; 95% CI,
0.96 to 1.21, for patients with baseline HgB $ 10 g/dL); a test
for interaction was not reported, but 95% CIs are widely
overlapping.
Clinical interpretation. As of the date of this publication,
the FDA-approved labels state that ESAs are indicated for
the treatment of anemia due to concomitant, myelosuppressive
chemotherapy that is expected to continue for at least 2
additional months after ESA initiation. The labels state that
ESAs are not indicated for use in patients with cancer receiving
myelosuppressive chemotherapy in whom the anemia can be
managed by transfusion. A boxed warning includes several
additional cautionary notes for use in cancer, including a
statement that ESAs are not indicated for patients receiving
myelosuppressive chemotherapy when the anticipated outcome
is cure.
Unfortunately, it cannot be determined from the available evidence
whether any particular group of potential ESA recipients has a greater
or lesser risk of harm than other patients with chemotherapy-induced
anemia. The mechanisms of harm are also unclear. The FDA-
approved label’s distinction between patients being treated with
curative versus palliative intent may assist clinicians as they
compare and discuss with patients the risk-to-benefit ratios of an ESA
versus RBC transfusions. The decision to limit the indication for ESAs
to patients undergoing chemotherapy for palliation (treatment intent) is
not based on direct comparative analyses of data from clinical trials of
ESA treatment based on the intent of any particular regimen used.
Rather, it is based on the known risks, such as increased risk for
thromboembolic events and short-term mortality and decreased
overall survival. These increased risks have been observed across
different patient groups.6,36 With currently available evidence, it is
not possible to determine a patient group that could safely use
ESAs.
Note also that determining the goal of treatment requires clinical
judgment. Examples of diseases for which the treatment goal
should generally be considered curative include (among others)
testicular cancer, first-line therapy of Hodgkin disease, and early-
stage solid tumors treated with adjuvant chemotherapy (eg,
breast, colon, early lung). The Expert Panel acknowledges the
FDA’s assessment that the reported benefits of ESAs may be
outweighed by risks considered unacceptable in patients who
might otherwise expect cure or moderate to long survival from
their chemotherapy. Clinicians are urged to exercise caution in
considering ESA use in patients with malignancy being treated
with curative intent. The Expert Panel stresses the importance of
including a detailed discussion between health care providers
and their patients about the potential harms and benefits of ESA
therapy.
FDA-approved labeling for each ESA also states, “Initiate…in
patients on cancer chemotherapy only if the hemoglobin is less
than 10 g/dL.” The Expert Panel accepts that, although
evidence is lacking to establish an optimal HgB threshold for
starting ESA therapy, it is clinically prudent to wait until HgB
concentration decreases to less than 10 g/dL. However, the
Expert Panel acknowledges that rare clinical circumstances
(such as severe pulmonary or cardiovascular comorbidities)
may warrant careful consideration of ESA use when HgB levels
are $ 10 g/dL.
In rare circumstances, patients with cancer and renal insuffi-
ciency may have concurrent indications for the use of ESAs.
Clinicians should also consider guidelines on ESA use for CKD-
related anemia under these circumstances.
Clinical question 2
To reduce the need for RBC transfusions, should ESAs be offered
to anemic patients with cancer who are not receiving concurrent
myelosuppressive chemotherapy?
Recommendation 2.1
ESAs should not be offered to most patients with nonchemotherapy-
associated anemia (Type: informal consensus; Evidence quality: low;
Strength of recommendation: strong).
Recommendation 2.2
ESAs may be offered to patients with lower-risk MDSs and a serum
erythropoietin level # 500 IU/L (Type: evidence based; Evidence
quality: intermediate; Strength of recommendation: moderate).
Literature review update and analysis. The recommendation
against ESA use in patients who are not receiving concomitant
myelosuppressive chemotherapy (with the exception noted in Recom-
mendation 2.2) has been reworded, but the intent is the same as in
2010. Recommendation 2.2 has been revised to specify serum
erythropoietin levels at which an ESA may be appropriate in MDS.
Two meta-analyses in the updated literature review presented
subgroup results by cancer treatment.2,14 Neither provided evidence
that would support a change to the Recommendation 2.1. In a 2014
meta-analysis of ESAs and fatigue,14 a benefit of ESAs was
numerically greatest among patients treated with chemotherapy,
although the test for interaction by type of cancer treatment was
not statistically significant (P = .22). In a 2012 meta-analysis,2 type
of cancer treatment did not qualify for inclusion in multivariate models
of ESA safety and efficacy.
In patients with MDS, one RCT evaluated the addition of epoetin
beta to lenalidomide in 131 patients with RBC transfusion-dependent,
low, or intermediate-1 risk (according to the International Prognostic
Scoring System), ESA refractory, nondel(5q) MDS.26 The combination
of lenalidomide and epoetin beta increased the frequency of erythroid
response relative to lenalidomide alone (39% v 23%; P = .04), but did
not significantly affect duration of erythroid response (15 v 18 months;
P = .64) or likelihood of transfusion independence (24% v 14%;
P = .13). In subgroup analyses, patients with lower baseline serum
erythropoietin levels had higher rates of erythroid response.
Clinical interpretation. There is no evidence that the relative
effects of ESAs to reduce the risk for RBC transfusions differ
in patients with and without myelosuppressive chemotherapy.
However, according to current licensing, ESAs are only indicated
in patients who are anemic from concurrent myelosuppressive
chemotherapy and not in patients with cancer who are not receiving
concurrent myelosuppressive chemotherapy.
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In patients with MDS, some studies suggest that patients with
elevated baseline erythropoietin levels (. 500 IU/L) are unlikely
to respond to ESA therapy.37 Furthermore, a recent study has
suggested that an even lower baseline erythropoietin level (, 200
IU/L) is associated with a better HgB response.38 ESAs should be
avoided in patients with MDS with elevated baseline erythropoietin
levels (. 500 IU/L). Lower pretreatment RBC transfusion de-
pendence (, 2 units per month) has also been associated with a
higher likelihood of ESA response in patients with MDS.39 Among
the potential benefits of ESA therapy in patients with MDS is
avoidance of secondary hemochromatosis, particularly for lower risk
patients who may have years of survival.
Clinical question 3
What special considerations apply to adult patients with non-
myeloid hematologic malignancies who are receiving concurrent
myelosuppressive chemotherapy?
Recommendation 3
In patients with myeloma, non-Hodgkin lymphoma, or chronic
lymphocytic leukemia, clinicians should observe the hematologic
response to cancer treatment before considering an ESA.
Particular caution should be exercised in the use of ESAs
concomitant with treatment strategies and diseases where risk of
thromboembolic complications is increased (see Recommenda-
tions 4 and 6). In all cases, blood transfusion is a treatment option
that should be considered (Type: informal consensus; Evidence
quality: low; Strength of recommendation: moderate).
Literature review update and analysis. The 2012 Cochrane
review by Tonia et al2 conducted subgroup analyses by cancer type
and provided results for mortality, RBC transfusion, thromboembo-
lism, and fatigue. Interactions by cancer type were nonsignificant
except for RBC transfusions: the reduction in risk of RBC
transfusion with ESA use was greatest among patients with solid
tumors. Other meta-analyses also evaluated subgroups of patients
with hematologic malignancies, but only in relation to a single
outcome: overall survival (nonsignificantly associated with ESA
use based on a single study of 60 patients with lymphoma),21
thromboembolism (increased risk with ESA use),16 or fatigue
(decreased risk with ESA use).14
Clinical interpretation. The FDA label now limits the indication for
ESA use to patients receiving chemotherapy for noncurative intent. In
patients with nonmyeloid hematologic malignancies, who are being
treated with palliative intent and in whom a short survival can be
reasonably expected, use of ESAs can be considered if anemia
does not improve with treatment of the underlying malignancy and
cannot be supported with transfusions due to logistical or personal
factors or preferences. However, given the recent advances in
the treatment of these diseases that have resulted in significant
improvements in survival, very careful consideration should be given
to the categorization of the treatment intent. Evaluation of individual
cases must be based on the intent of treatment and the life
expectancy for each patient. Because these malignancies recur in
most patients but multiple treatments are currently available for
this situation, determining the treatment intent and the expected
survival requires clinical judgment of an individual patient’s cir-
cumstances. Additionally, the risks of other complications, in
particular, thromboembolic events, must be taken into account
as many agents can increase the risk of this complication (eg,
immunomodulatory drugs in multiple myeloma). Finally, it should
be noted that there is little to no information regarding the risks
and benefits of the concurrent use of ESAs and newer agents,
such as monoclonal antibodies and targeted and cellular
therapies, and therefore, no recommendations can be issued in
this regard.
Clinical question 4
What examinations and diagnostic tests should be performed
before making a decision about using an ESA to identify patients
who are likely to benefit from an ESA?
Recommendation 4
Before offering an ESA, clinicians should conduct an appropriate
history, physical examination, and diagnostic tests to identify
alternative causes of anemia aside from chemotherapy or an
underlying hematopoietic malignancy. Such causes should be
appropriately addressed before considering the use of ESAs.
Suggested baseline investigations are listed in Table 1 (Type:
informal consensus; Evidence quality: intermediate; Strength of
recommendation: strong).
Literature review update and analysis. No new eligible
publications were identified by the updated literature review.
Clinical interpretation. Given the risks associated with the
use of ESAs, it is of the utmost importance to assess the need
for and the risks of their use. Therefore, changes to the previous
recommendations include clarification of the investigations sug-
gested in the work-up of anemia prior to considering the use of
ESAs since addressing reversible causes of anemia is the preferred
initial approach. Additionally, given the increased risk of thrombo-
embolism, evaluating thrombotic risk is very important. This is
addressed in Clinical Question 6.
Clinical question 5
Among adult patients who receive an ESA for chemotherapy-
associated anemia, do darbepoetin, epoetin beta and alfa originator,
and currently available biosimilars of epoetin alfa differ with respect to
safety or efficacy?
Table 1. Suggested baseline investigations for anemia in patients
with cancer receiving chemotherapy
Suggested investigation
Thorough drug exposure history
Review of a peripheral blood smear*
Analyses, where indicated, for iron, total iron-binding capacity, transferrin saturation, ferritin,
folate, vitamin B12, or hemoglobinopathy screening
Assessment of reticulocyte count, occult blood loss, and renal Insufficiency
Baseline erythropoietin level
Testing of serum thyroid-stimulating hormone level, where indicated
Investigations may also include direct antiglobulin testing (eg, Coombs test) for patients
with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or a history of autoimmune
disease
Suggestions are based on the consensus of the Expert Panel. This is not intended to be
a comprehensive list of investigations.
*And in some cases, a bone marrow examination.
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Recommendation 5
The Expert Panel considers epoetin beta and alfa, darbepoetin, and
biosimilar epoetin alfa to be equivalent with respect to effectiveness
and safety (Type: informal consensus; Evidence quality: intermedi-
ate; Strength of recommendation: moderate).
Literature review update and analysis. Three meta-analyses
conducted subgroup analyses by type of ESA (epoetin versus
darbepoetin).1,2,16 The two agents showed similar safety and efficacy.
One exception to this was reported in the 2012 Cochrane review
by Tonia et al.2 Epoetin was associated with a larger improvement
in fatigue than darbepoetin, but these results may have been
confounded by three darbepoetin trials without anticancer treatment.
The systematic review of biosimilar ESAs included two meta-
analyses27,28 and one RCT29 in patients with CKD, and one RCT30
and three cohort studies31-33 in patients with cancer. In a 2017
meta-analysis of RCTs in CKD, Amato et al27 reported that efficacy
and safety outcomes did not differ significantly between patients
treated with epoetin alfa originator or biosimilar but described the
quality of evidence as low to very low. A 2017 Cochrane review by
Hahn et al28 focused on short-acting ESAs in predialysis patients.
The review identified one trial of HX575 (a biosimilar of epoetin alfa),
but results were not available; the trial was stopped early when two
patients receiving HX575 developed antibodies to epoetin and pure
red cell aplasia. HX575 was also evaluated in a 2017 RCT by Weir
et al.29 The trial enrolled adults with end-stage renal disease who
were on dialysis and had been receiving stable doses of epoetin
alfa. Patients were randomly assigned to continue epoetin alfa or
to receive HX575. The two agents were similarly effective at
maintaining stable HgB levels. Binding anti-erythropoietin anti-
bodies developed in six patients (2.8%) in the HX575 arm and one
patient (0.5%) in the epoetin alfa arm, but no patients developed
neutralizing anti-erythropoietin antibodies.
The single RCT in patients with cancer was small: 60 patients
assigned to HX575 and 34 assigned to epoetin alfa were included
in the analysis.30 All patients had solid tumors and chemotherapy-
associated anemia. HX575 appeared to be effective with respect to
HgB response, but the possibility of bias in this study limits firm
conclusions. A large retrospective population-based cohort study in
Italy evaluated more than 13,000 new ESA users, 8161 with CKD
and 5,309 with cancer.33 A biosimilar epoetin alfa had been used by
154 (1.9%) of the patients with CKD and 453 (8.5%) of the patients
with cancer. Biosimilar and originator epoetin alfa had similar safety
and efficacy in both CKD and cancer with one exception: among
patients with cancer, biosimilar epoetin alfa was associated with
lower overall mortality than the originator (HR, 0.82; 95% CI, 0.70
to 0.97), but this finding is not conclusive because residual
confounding could not be excluded since more patients in the
originator group died of cancer activity. A retrospective study of
patients with MDS and refractory anemia evaluated 46 patients
treated with biosimilar epoetin alfa and 46 patients with originator
epoetin alfa. Median time to reach an HgB level . 12 g/dL was
10.5 weeks (range, 3 to 16 weeks) among patients treated with
the biosimilar and 12 weeks (range, 4 to 18 weeks) among
patients treated with the originator product.31 Finally, a retro-
spective study of 419 patients with cancer compared biosimilar
epoetin alfa with darbepoetin alfa.32 Mean HgB increase was
similar in the two groups. Blood transfusions were received by
8% of patients treated with biosimilar epoetin alfa and 14% of
patients treated with darbepoetin alfa (P = .04). These results
were confirmed in another Italian retrospective cohort study,
which did not find a difference in HgB response among new users
of either biosimilars or reference product of epoetin alfa or other
ESAs in either CKD or patients with cancer during the first
3 months of treatment.34
Clinical interpretation. Based on limited evidence, it seems
that compared with the originator, biosimilars of epoetin alfa are
safe and effective. However, the evidence is of moderate to low
quality, and this is derived from studies in patients with cancer and
CKD. Biosimilars have been available in Europe for over 10 years,
and no major concerns have arisen. In the United States, these
agents are more recent. Users should review pertinent ap-
provals and indications as per their local regulatory authori-
ties. Ultimately, the choice of a particular agent will depend on
cost, availability, convenience, and personal considerations or
preference.40,41
Clinical question 6
Do ESAs increase the risk of thromboembolism?
Recommendation 6
ESAs increase the risk of thromboembolism, and clinicians should
carefully weigh the risks of thromboembolism and use caution and
clinical judgmentwhen considering use of these agents (Type: evidence
based; Evidence quality: high; Strength of recommendation: strong).
Literature review update and analysis. The publications in the
updated review consistently report an increased risk of thromboem-
bolism in ESA-treated patients.1,2,6,16,19,25 This increased thrombo-
embolic risk with ESA use was observed across categories of
baseline HgB,2 type of cancer,2,16,25 and type of ESA.1,2,16
Clinical interpretation. Meta-analyses and individual RCTs
consistently report a 50%1,2 to 75%16,25 increased risk of thrombo-
embolism and vascular arterial events among patients receiving ESA
therapy. The Expert Panel continues to urge caution in the use
of ESAs for patients judged to be at increased risk for venous
thromboembolism. Several risk scores for predicting venous
thromboembolism have been developed; these are discussed in
more detail in the ASCO guideline on venous thromboembolism.42
Special attention should be given to patients with multiple myeloma
who are being treated with thalidomide or lenalidomide and
doxorubicin or corticosteroids since they are at particularly increased
thrombotic risk.43 There are no data from RCTs investigating
concomitant use of anticoagulants or aspirin to lessen this risk.
Clinical question 7
Among adult patients who will receive an ESA for chemotherapy-
associated anemia, what are recommendations for ESA dosing and
dose modifications?
Recommendation 7
It is recommended that starting and modifying doses of ESAs follow
FDA guidelines (see Table 2 for specific dosing information; Type:
informal consensus; Evidence quality: intermediate; Strength of
recommendation: moderate).
Literature review update and analysis. This recommendation
remains unchanged. No publications in the updated literature review
supported nonstandard dosing. Duration of treatment was analyzed in
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the 2012 Cochrane review and did not significantly modify the
association between ESA use and on-study mortality, overall
survival, likelihood of RBC transfusion, risk of thromboembolism,
or fatigue.2
Clinical interpretation. No new evidence suggests that out-
comes of ESA therapy would be improved by use of an initial dose
or dose modification regimen other than those in the FDA-approved
labels. Note that some aspects of the labels’ dose increase
recommendations have changed (Table 2).
Clinical question 8
Among adult patients who will receive an ESA for chemotherapy-
associated anemia, what is the recommended target HgB level?
Recommendation 8
HgB may be increased to the lowest concentration needed to avoid or
reduce the need for RBC transfusions, which may vary by patient and
condition (Type: informal consensus; Evidence quality: intermediate;
Strength of recommendation: moderate).
Literature review update and analysis. No new eligible
publications were identified by the updated literature review.
Clinical interpretation. An optimal target HgB concentration
cannot be definitively determined from the available literature.
Modification to reduce the ESA dose is appropriate when HgB
reaches a level sufficient to avoid transfusion or the increase
exceeds 1 g/dL in any 2-week period to avoid excessive ESA
exposure, considering the risks of ESAs. Specific dose-reduction
recommendations are provided in Table 2.
Clinical question 9
Among adult patients with chemotherapy-associated anemia who
do not respond to ESA therapy (, 1 to 2 g/dL increase in HgB or
no decrease in transfusion requirements), does continuation of ESA
therapy beyond 6 to 8 weeks provide a benefit?
Recommendation 9
ESAs should be discontinued in patients who do not respond within
6 to 8 weeks. Patients who do not respond to ESA treatment should
be reevaluated for underlying tumor progression, iron deficiency, or
other etiologies for anemia (Type: informal consensus; Evidence
quality: intermediate; Strength of recommendation: strong).
Literature review update and analysis. No publications in the
updated literature review addressed ESA continuation in
nonresponders.
Clinical interpretation. Given the known harms of ESAs, the
exposure to ESAs should be minimized. In patients who have
received appropriate ESA dosing (see Recommendation 7) and
who do not respond, ESAs should be stopped and not continued.
Clinical question 10
Among adult patients with chemotherapy-associated anemia, does
iron supplementation concurrent with an ESA reduce transfusion
requirements?
Recommendation 10
Iron replacement may be used to improve HgB response and
reduce RBC transfusions for patients receiving ESA with or without
iron deficiency. Baseline and periodic monitoring of iron, total
iron-binding capacity, transferrin saturation, or ferritin levels is
recommended (Type: evidence based; Evidence quality: interme-
diate; Strength of recommendation: weak).
Literature review update and analysis. The use of supple-
mental iron with an ESA was evaluated in three meta-
analyses.15,20,22 Compared with an ESA alone, a 2016 Cochrane
review by Mhaskar et al20 reported that the combination of an ESA
and iron increased the likelihood of hematopoietic response (RR,
1.17; 95% CI, 1.09 to 1.26) and reduced the likelihood of RBC
transfusion (RR, 0.74; 95% CI, 0.60 to 0.92) without significantly
Table 2. ESA adult dosing
Dose and
modifications Epoetin alfa* Darbepoetin alfa
Initial dose† 150 U/kg SC TIW‡ 40,000 U SC weekly§ 2.25 mg/kg SC weekly‡ 500 mg SC
Q3W§
Dose increases Increase dose to 300 U/kg SC TIW if HgB
increases by , 1 g/dL and remains below
10 g/dL after 4 weeks of therapy
Increase dose to 60,000 U SC weekly if HgB
increases by , 1 g/dL and remains below
10 g/dL after 4 weeks of therapy
Increase dose to 4.5 mg/kg weekly if HgB
increases by, 1 g/dL and remains below 10
g/dL after 6 weeks of therapy
N/A
Dose reductions Decrease dose by 25% when HgB reaches a level needed to avoid transfusion or HgB
increases . 1 g/dL in 2 weeks
Decrease dose by 40% when HgB reaches a level needed to
avoid transfusion or HgB increases . 1 g/dL in 2 weeks
Dose withholding If HgB exceeds a level needed to avoid transfusion, restart dose at 25% below previous
dose when HgB approaches a level where transfusion may be required
If HgB exceeds a level needed to avoid transfusion, restart dose
at 40% below previous dose when HgB approaches a level
where transfusion may be required
Discontinue‖ Following completion of chemotherapy course or if no response after 8 weeks of therapy
(measured by HgB levels or continuing need for transfusions)
Following completion of chemotherapy course or if no response
after 8 weeks of therapy (measured by HgB levels or
continuing need for transfusions)
Food and Drug Administration product labels were accessed on June 8, 2018, for epoetin (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5363s5366lbl.pdf) and
for darbepoetin (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103951s5374lbl.pdf).
ESA, erythropoiesis-stimulating agent; HgB, hemoglobin; N/A, not applicable; Q3W, every 3 weeks; SC, subcutaneously; TIW, three times per week.
*Including epoetin alfa-epbx.
†Initiate only if HgB is , 10 g/dL and there is a minimum of two additional months of planned chemotherapy. Use and dosing differ in patients with myelodysplastic syndromes.
‡Weight-based dose.
§Fixed dose.
‖Patients who do not respond to ESA treatment should be re-evaluated for underlying tumor progression, iron deficiency, or other etiologies for anemia.
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affecting risk of thromboembolism (RR, 0.95; 95% CI, 0.54 to 1.65)
or quality of life (standardized mean difference, 0.01; 95% CI,
20.10 to 0.12). Intravenous (IV) iron provided a greater benefit than
oral iron with respect to mean change in HgB level (IV iron mean
difference, 0.84; 95% CI, 0.21 to 1.46; P = .009; oral iron mean
difference, 0.07; 95% CI, 20.19 to 0.34; P = .59; P = .03 for
interaction). Route of iron administration did not significantly modify
the association with hematopoietic response (P = .16). Findings in
the two earlier meta-analyses15,22 were generally similar.
Clinical interpretation. This recommendation changed from pre-
vious versions based on new information published after the last
guideline. The Expert Panel believes that the use of iron supplemen-
tation in all patients receiving ESAs should be considered, independent
of the iron status. This is based on evidence that iron supplementation
reduces the risk for RBC transfusion. Additionally, in patients with
evidence of iron deficiency, the cause of the deficiency should be
investigated and corrected.
Oral and IV iron formulations are both acceptable options for iron
supplementation. Choice of agents depends on patient and doctor
preferences, formulation availability, cost, and comorbidities. IV iron
preparations have the advantage of being able to deliver larger
amounts of elemental iron in a single application and may also be
more adequate in patients with poor oral intake or absorption
problems. They have the disadvantages of being associated with
more serious systemic reactions and higher costs. There is some
limited evidence that IV iron is superior to oral iron based on
improvement in HgB level. However, the results were not consistent
across all other hematologic outcomes, and the quality of adverse
outcomes reporting was poor.15,20,22 Safety has been better
studied in a systematic review and meta-analysis in patients with
CKD, which showed no difference in mortality or serious adverse
events in patients receiving intravenous iron, although there were
more episodes of hypotension with IV iron.44
Discussion
Although the use of ESAs reduces the need for transfusions in
anemic patients with cancer receiving chemotherapy, it is associated
with increased complications, including higher mortality and increased
risk of thromboembolic and cardiovascular events. For these
reasons, the use of ESAs in cancer is now generally limited to
patients who are receiving chemotherapy with palliative intent and
who are expected to have short survival. The decision about using
ESAs must be made in this context and with a thorough discussion
regarding each patient’s preferences, priorities, values, and spiritual
needs.
Patient-clinician communication
Patient counseling regarding the risks and benefits of ESA therapy
is essential to ensure that patients are making informed decisions.
The Expert Panel encourages health care providers to have an open
dialogue with their patients to help them make informed decisions
by considering the scientific evidence and weighing their individual
risks with potential harms and benefits of ESA therapy.
In addition to providing a medication guide, health care providers
should discuss the following with patients considering ESA
therapy:
c When used, the goal of ESA therapy for patients with chemotherapy-
induced anemia is to reduce RBC transfusion requirements.
c The FDA has indicated that ESAs should not be given to
patients who are being treated for cancer when the goal is to
cure the patients of cancer.
c ESAs have been found to shorten overall survival and/or speed
tumor growth in some patients with cancer.
c ESAs have risks of adverse events, such as thromboembolism
(ie, blood clots), so individual risk factors need to be considered.
c ESAs are not recommended for patients with cancer who are
not receiving chemotherapy, except in the case of patients with
lower risk MDS.
For general recommendations and strategies to optimize patient-
clinician communication, see “Patient-Clinician Communication:
American Society of Clinical Oncology Consensus Guideline.”45
Health disparities
Although ASCO and ASH clinical practice guidelines represent
expert recommendations on the best practices in diseasemanagement
to provide the highest level of cancer care, it is important to note
that many patients have limited access to medical care. Racial and
ethnic disparities in health care contribute significantly to this
problem in the United States. Patients with cancer who are members
of racial/ethnic minorities suffer disproportionately from comorbid-
ities, experience more substantial obstacles to receiving care, are
more likely to be uninsured, and are at greater risk of receiving care of
poor quality than other Americans.46-49 Many other patients lack
access to care because of their geographic location and distance
from appropriate treatment facilities. Awareness of these dispar-
ities in access to care should be considered in the context of
this clinical practice guideline, and health care providers should
strive to deliver the highest level of cancer care to these vulnerable
populations.
Multiple chronic conditions
Creating evidence-based recommendations to inform treatment
of patients with additional chronic conditions, a situation in which
the patient may have two or more such conditions—referred to as
multiple chronic conditions (MCC)—is challenging. Patients with
MCC are a complex and heterogeneous population, making it difficult
to account for all of the possible permutations to develop specific
recommendations for care. In addition, the best available evidence
for treating index conditions, such as cancer, is often from clinical
trials whose study selection criteria may exclude these patients to
avoid potential interaction effects or confounding of results
associated with MCC. As a result, the reliability of outcome data
from these studies may be limited, thereby creating constraints
for expert groups to make recommendations for care in this
heterogeneous patient population.
As many patients for whom guideline recommendations apply pre-
sent with MCC, any treatment plan needs to consider the complexity
and uncertainty created by the presence of MCC and highlights
the importance of shared decision making regarding guideline use
and implementation. Therefore, in consideration of recommended
care for the target index condition, clinicians should review all other
chronic conditions present in the patient and take those conditions
into account when formulating the treatment and follow-up plan.
In light of these considerations, practice guidelines should provide
information on how to apply the recommendations for patients with
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MCC, perhaps as a qualifying statement for recommended care.
This may mean that some or all of the recommended care options
are modified or not applied, as determined by best practice in
consideration of any MCC.
Cost implications
Increasingly, individuals with cancer are required to pay a larger
proportion of their treatment costs through deductibles and
coinsurance.50,51 Higher patient out-of-pocket costs have been
shown to be a barrier to initiating and adhering to recommended
cancer treatments.52,53
Discussion of cost can be an important part of shared decision
making.54 Clinicians should discuss with patients the use of less
expensive alternatives when it is practical and feasible for treatment
of the patient’s disease and there are two or more treatment options
that are comparable in terms of benefits and harms.54
Table 3 shows estimated prices for the available treatment options
addressed in this guideline. Of note, medication prices may vary
markedly, depending on negotiated discounts and rebates.
Patient out-of-pocket costs may vary depending on insurance
coverage. Coverage may originate in the medical or pharmacy
benefit, which may have different cost-sharing arrangements.
Patients should be aware that different products may be preferred or
covered by their particular insurance plan. Evenwith the same insurance
plan, the price may vary between different pharmacies. When
discussing financial issues and concerns, patients should be made
aware of any financial counseling services available to address this
complex and heterogeneous landscape.54
Open comment
The draft recommendations were released to the public for open
comment from August 15, 2018, through August 29, 2018.
Response categories of “Agree as written,” “Agree with suggested
modifications,” and “Disagree. See comments” were captured
for every proposed recommendation with two written comments
received. Both respondents either agreed or agreed with slight
modifications to the recommendations. Expert Panel members
reviewed comments from all sources and determined whether to
maintain original draft recommendations, revise with minor language
changes, or consider major recommendation revisions. All changes
were incorporated prior to ASCO Clinical Practice Guidelines
Committee review and approval.
Guideline implementation
ASCO and ASH guidelines are developed for implementation
across health settings. Barriers to implementation include the need
to increase awareness of the guideline recommendations among
front-line practitioners, survivors of cancer, and caregivers, as well
as the need to provide adequate services in the face of limited
resources. The guideline Bottom Line Box was designed to facilitate
implementation of recommendations. This guideline will be distrib-
uted widely through the ASCO Practice Guidelines Implementation
Network. ASCO and ASH guidelines are posted on each
organization’s Web site, and this guideline is jointly published in
JCO and Blood Advances.
Limitation of the research and
future research
There is clear evidence regarding the ability of ESAs to increase
HgB and avoid transfusions. There is also very consistent evidence
of harm associated with their use across a spectrum of conditions.
Since in recent years the number of new trials is somewhat limited
yet consistent with previous findings, we believe that rather than
focusing on the occurrence of adverse effects, the most pressing
Table 3. Estimated prices of ESAs and supplemental iron
Agent
HCPCS
code dosage
Medicare payment
limit (US$) Initial dose Regimen Price
ESAs
Darbepoetin alfa (non-ESRD) 1 mg 3.779 2.25 mg/kg SC Weekly (SC) $1,785.58 per 3-week cycle*
500 mg SC Every 3 weeks (SC) $1,889.50 per 3-week cycle
Epoetin alfa (non-ESRD) 1,000 U 13.333 150 U/kg 3 times weekly (SC) $1,259.97 per 3-week cycle*
40,000 U Weekly (SC) $1,599.96 per 3-week cycle
Iron supplements
Iron dextran 50 mg 13.669 Variable IV $273.38 per 1,000 mg
Ferric gluconate 12.5 mg 2.179 Variable IV $174.32 per 1,000 mg
Iron sucrose 1 mg 0.234 Variable IV $234.00 per 1,000 mg
Ferrous sulfate N/A N/A Variable Oral Available over the counter. Prices at a
sample of online retailers ranged from
$0.01-$0.11 per 325-mg tablet
Drug prices were estimated from a third-party payer perspective, based on reimbursement rates from the Centers for Medicare and Medicaid Services that are widely accepted by
providers, computed at the manufacturer’s average sales price. Other treatment-related direct and indirect costs were not considered, such as diagnostic laboratory tests. Actual treatment
costs and reimbursement will vary considerably across regions, payers, institutions, and practices, as well as over time, and readers should consult current local cost information specific to
their practice setting. Costs were based on Medicare Part B payment allowance limits effective July 1, 2018 (with no administration fees or other adjustments; Medicare Part B Drug
Average Sales Price: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2018ASPFiles.html).
ESAs, erythropoiesis-stimulating agents; ESRD, end-stage renal disease; HCPCS, Healthcare Common Procedure Coding System; IV, intravenously; N/A, not applicable; SC,
subcutaneously.
*Based on an adult weighing 70 kg.
23 APRIL 2019 x VOLUME 3, NUMBER 8 ASCO/ASH ESA GUIDELINE UPDATE 1207
.For personal use onlyon May 9, 2019. by guest  www.bloodadvances.orgFrom 
need for additional research is studies that further clarify the
mechanisms of harm and, particularly, the groups of patients or
circumstances of clinical use that are least associated with these
risks. This information is paramount to the ability of clinicians to
extend the benefit of these drugs while reducing the risks.
Editor’s note
This American Society of Clinical Oncology (ASCO) and American
Society of Hematology (ASH) Clinical Practice Guideline provides
recommendations, with comprehensive review and analyses of
the relevant literature for each recommendation. Additional infor-
mation, including a Data Supplement with additional evidence tables,
slide sets, clinical tools and resources, and links to patient information
at www.cancer.net, is available at www.asco.org/supportive-care-
guidelines and is available as a supplement to the Blood Advances
version of the article. Additional evidence-based clinical practice
guidelines are also available at www.hematology.org/guidelines.
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